Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Short Interest Update

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) saw a significant decrease in short interest in the month of August. As of August 31st, there was short interest totalling 2,900,000 shares, a decrease of 16.2% from the August 15th total of 3,460,000 shares. Approximately 5.3% of the company’s shares are short sold. Based on an average daily volume of 541,500 shares, the short-interest ratio is presently 5.4 days.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on the company. Royal Bank of Canada raised their price objective on shares of Agios Pharmaceuticals from $53.00 to $55.00 and gave the stock an “outperform” rating in a report on Friday, August 2nd. The Goldman Sachs Group boosted their price objective on Agios Pharmaceuticals from $33.00 to $53.00 and gave the company a “neutral” rating in a research note on Tuesday, June 4th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Agios Pharmaceuticals in a report on Monday, June 17th. JPMorgan Chase & Co. reiterated a “neutral” rating and set a $46.00 price target on shares of Agios Pharmaceuticals in a research note on Thursday, June 13th. Finally, StockNews.com lowered shares of Agios Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Monday, August 5th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and two have assigned a buy rating to the company’s stock. According to MarketBeat, Agios Pharmaceuticals currently has an average rating of “Hold” and an average price target of $51.33.

Insiders Place Their Bets

In related news, CEO Brian Goff sold 11,091 shares of the business’s stock in a transaction on Thursday, August 8th. The stock was sold at an average price of $42.75, for a total transaction of $474,140.25. Following the completion of the transaction, the chief executive officer now directly owns 78,792 shares of the company’s stock, valued at approximately $3,368,358. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 4.93% of the company’s stock.

Institutional Investors Weigh In On Agios Pharmaceuticals

Institutional investors and hedge funds have recently made changes to their positions in the business. Acadian Asset Management LLC acquired a new stake in Agios Pharmaceuticals during the 2nd quarter valued at $37,000. Quest Partners LLC purchased a new stake in Agios Pharmaceuticals during the 2nd quarter worth about $40,000. North Star Asset Management Inc. purchased a new stake in Agios Pharmaceuticals during the 2nd quarter worth about $216,000. XTX Topco Ltd acquired a new position in Agios Pharmaceuticals in the 2nd quarter valued at about $230,000. Finally, Northcape Wealth Management LLC purchased a new position in Agios Pharmaceuticals in the 2nd quarter valued at about $244,000.

Agios Pharmaceuticals Price Performance

Shares of AGIO stock opened at $46.69 on Monday. The business’s fifty day moving average price is $45.45 and its 200 day moving average price is $38.74. The firm has a market capitalization of $2.66 billion, a PE ratio of -7.39 and a beta of 0.75. Agios Pharmaceuticals has a 1-year low of $19.80 and a 1-year high of $50.35.

Agios Pharmaceuticals (NASDAQ:AGIO) last released its quarterly earnings data on Thursday, August 1st. The biopharmaceutical company reported ($1.69) EPS for the quarter, missing analysts’ consensus estimates of ($1.60) by ($0.09). The company had revenue of $8.60 million for the quarter, compared to analysts’ expectations of $9.34 million. Agios Pharmaceuticals had a negative return on equity of 47.05% and a negative net margin of 1,165.69%. The firm’s quarterly revenue was up 28.4% on a year-over-year basis. During the same period in the prior year, the firm posted ($1.51) EPS. Equities research analysts expect that Agios Pharmaceuticals will post -4.85 earnings per share for the current fiscal year.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.